期刊文献+

阿托伐他汀减轻博莱霉素诱导的肺纤维化及其机制

Atorvastatin attenuates Bleomycin-induced pulmonary fibrosis in rats
下载PDF
导出
摘要 目的研究阿托伐他汀对博莱霉素诱导的大鼠肺纤维化的调节作用及其机制。方法雄性Wistar大鼠32只随机分为阿托伐他汀干预组(A组)、博来霉素组(B组)及正常对照组(C组)大鼠气管内灌注博来霉素5 mg/kg建立肺纤维化模型,A组在博莱霉素后给予阿托伐他汀灌胃10 mg/(kg.d),分别于第7、28天处死一半,病理学观察肺泡炎及肺纤维化程度,生化法测定肺组织羟脯氨酸含量,ELISA法检测肺泡灌洗中IFN-γ、IL-4的浓度,比较组间变化。结果与C组相比,B组大鼠出现明显的肺泡炎及纤维化,而阿托伐他汀可显著减轻肺纤维化程度。BALF中,B组IL-4升高而IFN-γ降低,阿托伐他汀干预可部分逆转这种变化。结论阿托伐他汀可能通过调节Th1/Th2平衡而减轻博莱霉素诱导的大鼠肺纤维化。 【Objective】 To study the immunoregulatory effect of Atorvastatin,a 3-hydroxy-3-methyl-glutaryl coenzyme A(HMG-CoA) reductase inhibitor,on Bleomycin-induced pulmonary fibrosis in rats and its possible mechanism.【Methods】 Pulmonary fibrosis was induced in Wistar rats by intratracheal instillation of Bleomycin(5 mg/kg).Subsequently,the rats received daily Atorvastatin(10 mg/kg) orally.Four to six rats in each group were sacrificed 7 and 28 days after intratracheal instillation.Histological changes in the lungs were evaluated by hematoxylin-eosin and masson stain and scored.Hydroxyproline contents in lung tissues were detected.The levels of IFN-γ and IL-4 in bronchoalveolar lavage fluid(BALF) were measured by ELISA.【Results】 Inflammatory cell infiltration and fibrotic scores were more prominent in the model group compared to the control group.Hydroxyproline contents in lung tissue were significantly increased 28 days after intratracheal Bleomycin instillation.Atorvastatin apparently attenuated the degree of pulmonary fibrosis.Further study showed that Atorvastatin significantly increased IFN-γ levels while decreasing IL-4 levels in lung BALF.【Conclusions】 Atorvastatin had an inhibitory effect on Bleomycin-induced pulmonary fibrosis.This effect may be associated with its regulation on Th1/Th2 balance in the lung.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2011年第8期919-923,共5页 China Journal of Modern Medicine
关键词 肺纤维化 博莱霉素 阿托伐他汀 TH1/TH2平衡 pulmonary fibrosis Bleomycin Atorvastatin Th1/Th2 balance
  • 相关文献

参考文献15

  • 1FEGHALI-BOSTWICK CA, TSAI CG, VALENTINE VG, et al. Cellular and humoral autoreaetivity in idiopalhie pulmonary fibre- sis[J]. Journal Immunol, 2007, 179: 2592-2599.
  • 2JINDAL SK, AGARWAL R. Autoimmunity and interstitial lung disease [J]. Curr Opin Pulm Med, 2005, 11: 438-446.
  • 3LUKACS NW, HOGABOAM C, CHENSUE SW, et al. Type 1/type 2 eytokine paradigm and the progression of pulmonary fi- brosis[J]. Chest, 2001, 120 (1 Suppl): S5-S8.
  • 4KUNKEL SL, CHENSUE SW, LUKACS N, et al. Cytokine phenotypes serve as a paradigms for experimental immune-medi- ated lung diseases and remodeling [J]. Am Journal Respir Cell Mol Biol, 2003, 29 (3 Suppl): S63-S66.
  • 5SZAPIEL SV, ELSON NA, FULMER JD, et al. Bleomyein-in- duced interstitial pulmonary diseases in the nude, athymic mouse [J]. Am Rev Resp Dis, 1979, 120: 893-895.
  • 6SIME PJ, O'REILLY KM. Fibrosis of the lung and other tis- sues: new concepts in pathogenesis and treatment [J]. Clin Im- munol, 2001, 99: 308-319.
  • 7SHIMIZU Y, KUWABARA H, ONO A, et al. Intracellular Th1/Th2 balance of pulmonary CD4T cells in patients with active interstitial pneumonia evaluated by serum KL-6[J]. Immunophar- macol Immunotoxicol, 2006, 28(2): 295-304.
  • 8PIGNATTI P, BRUNETFI G, MORETTO D, et al. Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fi- brosis[J]. Am J Respir Crit Care Med, 2006, 173: 310-317.
  • 9YOSHINOUCHI T, NANIWA T, SHIMIZU S, et al. Expression of chemokine receptors CXCR3 and CCR4 in lymphocytes of id- iopathic nonspecific interstitial pneumonia [J]. Respir Med, 2007, 101(6): 1258-1264.
  • 10KIKUCHI N, ISHII Y, MORISHIMA Y, et al. Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance [J]. Respiratory Research, 2010, 11: 31-42.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部